MedTrace Logo

Study of Stereotactic Ablative Radiotherapy (SABR) in Elderly Stage I NSCLC

NCT02584699 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2015-10-23

No results posted yet for this study

Summary

This study aims to prospectively investigate the efficacy, toxicity and quality of life (QOF) of stereotactic ablative radiotherapy (SABR) using a moderate fractionation of 72 Gy/6 Gy/12 F (BED10 = 115 Gy) in a single arm of elderly ( ≥ 70) patients with stage I (2009 UICC) non-small cell lung cancer (NSCLC).

Conditions

Interventions

RADIATION

Stereotactic Ablative Radiotherapy (SABR)

Six Gy irradiation per fraction times 12 fractionations, resulting a total dose of 72Gy

Sponsors & Collaborators

  • Luhua Wang

    lead UNKNOWN

Principal Investigators

  • Jingbo Wang, Dr. · Cancer Hospital/Institute, Chinese Academy of Medical Sciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2018-07-31
Completion
2018-07-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02584699 on ClinicalTrials.gov